The Differential Effect of Risperidone and Olanzapine on Insulin Sensitivity after 3 Weeks of Treatment: A HOMA Pilot Study

G. Paslakis; M. Deuschle; J. Thome; S. Rüße; D. Kopf

doi:10.1055/s-0031-1297935

Pharmacopsychiatry, Inhaltsverzeichnis

Pharmacopsychiatry 2012; 45(03): 96-99
DOI: 10.1055/s-0031-1297935

Original Paper

The Differential Effect of Risperidone and Olanzapine on Insulin Sensitivity after 3 Weeks of Treatment: A HOMA Pilot Study

G. Paslakis

¹Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, Mannheim, Germany

,

M. Deuschle

¹Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, Mannheim, Germany

,

J. Thome

¹Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, Mannheim, Germany

²Department of Psychiatry and Psychotherapy, University of Rostock, Rostock, Germany

,

S. Rüße

¹Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, Mannheim, Germany

,

D. Kopf

¹Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, Mannheim, Germany

› Institutsangaben

Abstract

Background and Methods:

Patients with an acute psychotic episode underwent HOMA testing for insulin sensitivity (IS) prior to and after 3 weeks of treatment with olanzapine (n=7) or risperidone (n=7).

Results and Discussion:

The HOMA-IS index was reduced in the olanzapine group, but significantly increased in patients treated with risperidone. There was a significant “time×medication” interaction (p=0.03). The BMI significantly increased as a result of both treatments. IS can be acutely ameliorated by antipsychotic treatment with risperidone despite weight increase.

Conclusions:

Compared to risperidone, the IS is impaired after a 3-week treatment with olanzapine. Already short-term antipsychotic treatment may have effects on insulin sensitivity.

Key words

risperidone - olanzapine - HOMA - insulin sensitivity - BMI

Volltext

Referenzen

References
1 Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601
2 Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 2005; 66: 504-514
3 Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (Suppl. 01) 1-93
4 Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223
5 Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004; 65 (Suppl. 18) 36-46
6 Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007; 21: 911-936
7 Bonora E, Targher G, Alberiche M et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63
8 Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens 1998; 16: 895-906
9 Stumvoll M, Mitrakou A, Pimenta W et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000; 23: 295-301
10 Sernyak MJ, Leslie DL, Alarcon RD et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159: 561-566
11 Wirshing DA, Boyd JA, Meng LR et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63: 856-865
12 Hardy TA, Henry RR, Forrester TD et al. Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. Diabetes Obes Metab 2011; 13: 726-735
13 Newcomer JW, Ratner RE, Eriksson JW et al. 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry 2009; 70: 487-499
14 Smith RC, Lindenmayer JP, Davis JM et al. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. J Clin Psychiatry 2009; 70: 1501-1513
15 Deibert DC, DeFronzo RA. Epinephrine-induced insulin resistance in man. J Clin Invest 1980; 65: 717-721
16 Houseknecht KL, Robertson AS, Zavadoski W et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007; 32: 289-297
17 Sacher J, Mossaheb N, Spindelegger C et al. Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology 2008; 33: 1633-1641
18 Koller E, Schneider B, Bennett K et al. Clozapine-associated diabetes. Am J Med 2001; 111: 716-723
19 Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002; 22: 841-852
20 Vidarsdottir S, Roelfsema F, Frolich M et al. Olanzapine shifts the temporal relationship between the daily acrophase of serum prolactin and cortisol concentrations rhythm in healthy men. Psychoneuroendocrinology 2009; 34: 705-712
21 Henderson DC, Cagliero E, Copeland PM et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005; 62: 19-28
22 Sowell M, Mukhopadhyay N, Cavazzoni P et al. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab 2003; 88: 5875-5880
23 Baptista T, Martinez M, Lacruz A et al. Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia. Schiz Res 2007; 89: 350-352